Payment overview · 2025
General Payments
$122.76
5 reported records · 4 companies
Healthcare provider profile · identity verified
Robert Callahan, MD
Allopathic & Osteopathic Physicians|Family Medicine · DES MOINES, IA · NPI 1174532865
Verified facts
What the public records show
CMS Open Payments records show Robert Callahan, MD received $122.76 in general payments during 2025 across 5 reported records.
Lilly USA, LLC accounted for 40.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.79 | 40.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.54 | 26.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.44 | 16.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.99 | 16.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $122.76 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $69.78 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.44 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.44 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 161 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
161 | 27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
161 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
79 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 658 | 160 |
| Levothyroxine Sodium | Levothyroxine Sodium | 396 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 348 | 96 |
| Lisinopril | Lisinopril | 335 | 85 |
| Omeprazole | Omeprazole | 280 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 252 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 246 | 69 |
| Metformin Hcl Er | Metformin Hcl | 221 | 56 |
| Simvastatin | Simvastatin | 178 | 45 |
| Potassium Chloride | Potassium Chloride | 167 | 39 |
| Sertraline Hcl | Sertraline Hcl | 166 | 35 |
| Jardiance | Empagliflozin | 161 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 37 |
| Gabapentin | Gabapentin | 151 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 40 |
| Glimepiride | Glimepiride | 146 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 127 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 126 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 46 |
| Trazodone Hcl | Trazodone Hcl | 111 | 25 |
| Tramadol Hcl | Tramadol Hcl | 110 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 26 |
| Losartan Potassium | Losartan Potassium | 108 | 34 |
| Lorazepam | Lorazepam | 101 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 91 | 15 |
| Allopurinol | Allopurinol | 90 | 19 |
| Mounjaro | Tirzepatide | 79 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 78 | 17 |
| Metformin Hcl | Metformin Hcl | 76 | 19 |
| Ezetimibe | Ezetimibe | 74 | 19 |
| Famotidine | Famotidine | 74 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 16 |
| Xarelto | Rivaroxaban | 73 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 69 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 16 |
| Eliquis | Apixaban | 65 | 16 |
| Clonazepam | Clonazepam | 64 | suppressed |
| Furosemide | Furosemide | 63 | 17 |
| Meloxicam | Meloxicam | 62 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 20 |
| Alprazolam | Alprazolam | 58 | 15 |
| Finasteride | Finasteride | 56 | 12 |
| Naproxen | Naproxen | 49 | 20 |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 42 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 42 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Ozempic | Semaglutide | 40 | 12 |
| Atenolol | Atenolol | 39 | suppressed |
| Mirtazapine | Mirtazapine | 38 | 11 |
| Dutasteride | Dutasteride | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 11 |
| Tradjenta | Linagliptin | 36 | suppressed |
| Linzess | Linaclotide | 35 | suppressed |
| Rybelsus | Semaglutide | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 28 |
| Carvedilol | Carvedilol | 34 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Prednisone | Prednisone | 31 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Nystatin | Nystatin | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 20 |
| Cephalexin | Cephalexin | 26 | 25 |
| Spironolactone | Spironolactone | 26 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 16 |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Dulera | Mometasone/Formoterol | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Primidone | Primidone | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 12 |
| Digoxin | Digoxin | 12 | suppressed |
| Diovan Hct | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $122.76 · 5 records | Lilly USA, LLC | JARDIANCE, Ozempic, QULIPTA, Rybelsus, UBRELVY, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error